<div><br></div><div><span style="font-size:16pt;">Who We Are</span></div><div><span style="font-size:11pt;">Technology has transformed almost every single aspect of our lives. Yet, it still takes 12 years to develop a drug. Today thousands of diseases affecting hundreds of millions of people have no effective treatment. Accelerating the pace of bringing effective, new medicines to patients is one of the greatest opportunities for humanity. Our mission is to develop better drugs, faster using technology. We have built an end-to-end technology-driven drug discovery platform centered around one of the field’s largest human genomics databases in neuroscience. We use aspects of machine learning to map the complex causes of disease and turn those insights into promising drug candidates on our internal biology and chemistry platforms. We are developing drugs to treat some of the biggest medical challenges today: ALS, Parkinson’s Disease, and Alzheimer’s Disease. Our first drug entered the clinic in October 2022 as a new treatment for ALS and was discovered entirely from our platform. We have raised $134M from top tier investors (e.g. BlackRock, Eli Lilly, Merck, Section 32, Threshold Ventures, Y Combinator, etc) and in 2021 we announced a $706M deal with Eli Lilly. We are a team of data scientists, neuroscientists, and drug developers united around an audacious vision: to build the next Genentech of the digital age. </span></div><div><br></div><div><span style="font-size:24px;">Who You Are</span></div><div><span style="font-size:11pt;">The Target Identification and Exploratory Biology department is seeking creative and driven scientists of all levels to develop state-of-the-art in vitro models representing neurodegenerative and psychiatric disorders using stem cell technology, organoids, 3D co-cultures and microfluidics. </span></div><div><br></div><div><span style="font-size:11pt;">This bench scientist position plays a central role in the Verge Genomics pipeline, intersecting with target validation and drug discovery groups. With your expertise in stem cell and CRISPR technologies, you will generate different brain cell-types and engineer disease mutations, pathway reporters, and drug target constructs. You will profile quality, functionality and disease relevance of the in vitro brain models (e.g., imaging, single cell RNAseq, spatial transcriptomics, proteomics). You will benchmark the in vitro models by validating targets identified by Verge Genomics computational platform.</span></div><div><br></div><div><span style="font-size:14.6667px;">These are future opportunities positions to help build our pipeline for early 2023. We encourage scientists of all levels to apply.</span></div>